La cadena de opciones muestra datos clave de las opciones de acciones de Baosheng Media Gr a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Baosheng Media Gr..

Baosheng Media Gr (NASDAQ:BAOS) Bolsa, Cadena de Opciones

Baosheng Media Gr

Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.

Baosheng Media Group Holdings Limited - Ordinary shares

Baosheng Media Group Holdings Ltd

<p>The uranium trade just went nuclear &#8211; in a good way. <a href="https://www.benzinga.com/topic/uranium">Uranium stocks are</a> on track for their 11th consecutive green week, marking the longest winning streak in the sector's history.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Uranium Stocks on track for an 11th consecutive green week, their longest winning streak in history &#x1f4c8;&#x1f4c8; <a href="https://t.co/QDHXRGhnDh">pic.twitter.com/QDHXRGhnDh</a></p>
<p>&mdash; Barchart (@Barchart) <a href="https://twitter.com/Barchart/status/1934660138582802588?ref_src=twsrc%5Etfw">June 16, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>That's not just bullish &#8211; it's historically unprecedented, and it's turning heads on Wall Street.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/01/43333616/uranium-sector-heating-up-in-2025-despite-a-deepseek-cooldown">Uranium Sector Heating Up In 2025 Despite A DeepSeek Cooldown</a></strong></p>
<h2 class="wp-block-heading">Why Uranium&#8217;s Heating Up</h2>
<p>Behind the surge is a combination of tight supply, rising demand, and a geopolitical backdrop that's becoming increasingly favorable for nuclear energy. Uranium spot prices have jumped nearly 30% year-to-date, with buyers scrambling to secure future supply as global stockpiles dwindle.</p>
<p>Governments are changing their tune. France is committing to new reactors, and Japan is reactivating nuclear plants post-Fukushima. Even in the U.S., nuclear is no longer a third-rail issue—the administration's Inflation Reduction Act allocates billions to support domestic nuclear fuel development.</p>
<p>Investors have noticed. The <strong>Sprott Uranium Miners ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URNM#NYSE">URNM</a>) and Global X Uranium ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URA#NYSE">URA</a>) have soared more than 27% YTD, handily outperforming the S&amp;P 500.</p>
<p>Meanwhile, uranium majors like <strong>Cameco Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) and NexGen Energy Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) are up over 35% and 28% respectively, over the same stretch.</p>
<h2 class="wp-block-heading">What Makes This Rally Different</h2>
<p>Unlike past uranium spikes driven by hype, this rally is grounded in fundamentals. The world's push for decarbonization is putting nuclear and uranium in the spotlight. Utilities are returning to long-term uranium contracting after years of underinvestment and supply-side stagnation.</p>
<p>Retail interest is picking up, too. Google search trends for "uranium stocks" have hit multi-year <a href="https://trends.google.com/trends/explore?date=today%203-m&amp;geo=US&amp;q=uranium%20stocks&amp;hl=en">highs</a>, and uranium-focused subreddits are seeing traffic spikes. The uranium narrative is no longer niche &#8211; it's becoming mainstream.</p>
<p>For U.S. investors, CCJ remains the blue-chip play. NXE, <strong>Denison Mines Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNN#NYSE">DNN</a>) and <strong>Energy Fuels Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#NYSE">UUUU</a>) offer higher-risk, higher-reward exposure. URNM and URA provide diversified bets on the entire value chain.</p>
<p>If this 11-week winning streak is any indication, the uranium bull market is not just alive—it's glowing.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45752230/3-nuclear-stocks-with-catalysts-as-energy-policy-ai-push-uranium-back-in-play">3 Nuclear Stocks With Catalysts As Energy Policy, AI Push Uranium Back In Play</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Commodities

Markets

Nuveen Arizona Dividend Advantage Municipal Funds 3

URNM

UUUU

Uranium Stocks On 11-Week Tear - Their Longest Winning Streak In History

News

CTVA

Micropep Technologies And Corteva Announce Multi-Year Research And Development Collaboration Through Corteva Catalyst Platform To Co-Develop Next-Generation Peptide-Based Biocontrol Solutions

<p>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) ("Robin Energy" or the "Company"), an international ship-owning company providing energy transportation services globally, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 860,000 common shares at an offering price of $5.25, for gross proceeds of approximately $4.5 million (the "Offering"), before deducting commissions and offering expenses, in a registered direct offering.</p>
<p>Maxim Group LLC is acting as the sole placement agent for the Offering.</p>
<p>Robin Energy currently intends to use the net proceeds from the Offering for working capital and general corporate purposes. The Offering is expected to close on or about June 20, 2025 (the "Closing Date"), subject to the satisfaction of customary closing conditions.</p>
<p>The Offering is being made pursuant to an effective shelf registration statement on Form F-3, (File No. 333-286726) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission ("SEC") on April 28, 2025. A prospectus supplement relating to the securities to be issued in the Offering will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the Offering, together with the accompanying prospectus, can be obtained at the SEC's website at <a href="https://www.globenewswire.com/Tracker?data=AbHLdwBdF8N0fr_0nz28IcGukaLXoAM--eus1fYjJdNUKNlS2OQ8XQ7Hxu8g2rMm2hWydAPs4-6CrVDBO-MvFA==">www.sec.gov</a> or by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at <a href="https://www.globenewswire.com/Tracker?data=gDJTicQoYgCmkspk0YotkXfgcAJnXQImAUINHFhIdLLrYu_pLViDWicvmilrEQs70U9BtlNr3rOEKb6vuEsfXHKOI8gJSZRqnpuBOt64RBU=">syndicate@maximgrp.com</a> or by telephone at (212) 895-3745.</p>


Offerings

RBNE

Robin Energy Announces Pricing Of $4.5M Registered Direct Offering For 860K Shares At A Purchase Price Of $5.25 Per Share

<p>Lake Street  analyst Ben Klieve   initiates coverage on TAT Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) with a Buy rating and announces Price Target of $37.</p>


Price Target

Initiation

Analyst Ratings

TATT

Lake Street Initiates Coverage On TAT Technologies with Buy Rating, Announces Price Target of $37

CWAN

HG Re Selects Clearwater To Enhance Investment Performance Measurement And Risk Analytics Capabilities

Wix Acquires Base44 For Initial Consideration Of $80M Plus Additional Earn-Out Payments Through 2029

<p><a href="https://www.globenewswire.com/Tracker?data=Ocixc6lSAxZTpzZKfdMiy7cZyw1AtCjjtFt0bAZ5qHgaAVuj9gHBAYyVDoVkAm3PI0wmnTqub3XgcgYc-pePyQ==">Intapp</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms,today announced a new strategic collaboration with Snowflake, the AI Data Cloud company. Intapp client firms will now be able to quickly build and apply analytics across a broad set of firmwide data in the Snowflake AI Data Cloud, then leverage that information within <a href="https://www.globenewswire.com/Tracker?data=Ocixc6lSAxZTpzZKfdMiyxvbv2SaMRLSwi77eFijcMF0Ff_lzSTre0S_Nf3pkE1a98e-qyVgpwFNWYdLcsLPVPIMRBmsG74TeYc42_LqKDQ=">Intapp DealCloud</a> to further enrich their deal management capabilities.&nbsp;&nbsp;</p>
<p>This collaboration brings together Snowflake's ability to combine data across key systems and DealCloud's robust deal management capabilities which are underpinned by AI-powered workflows and data models. By leveraging the Snowflake AI Data Cloud, Intapp is helping advisory, capital markets, and legal firms to more easily apply analytics to their most relevant deal data.</p>
<p>"Our clients are increasingly seeing the value in eliminating data silos across their firms and are turning to Snowflake to help them in this quest," said Erin Guinan, General Manager of DealCloud at Intapp. "Forging this connection with Snowflake lets firms more easily build and apply analytics with firmwide data that inform deal-related decision-making and embed that information back into key workflows within DealCloud."</p>
<p>"Intapp's commitment to helping Snowflake empower every enterprise to achieve its full potential through data and AI can be seen through the launch of our new integration with DealCloud," said Rinesh Patel, Global Head of Financial Services at Snowflake. "We look forward to driving deeper value for joint customers by working with Intapp to allow firms to access richer insights across broad data sets underpinned by the proprietary insights they capture and manage in DealCloud."</p>


Contracts

INTA

SNOW

Intapp Enters Collaboration With Snowflake To Help Quickly Build And Apply Analytics Across A Broad Set Of Firmwide Data

<p><i>Advanced AI agents from Agora and&nbsp;WIZ.AI can power call centers with multilingual support and contextual understanding</i></p>
<p>SANTA CLARA, Calif., June 18, 2025 /PRNewswire/ -- Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>), a global leader in real-time engagement and conversational AI technology, today announced its partnership with&nbsp;WIZ.AI to bring enterprise-grade AI agent solutions to the market.</p>
<p>Through the partnership, Agora will be integrated with WIZ.AI's tools for:</p>
<ul>
<li><strong>Inbound Customer Service: </strong>Enterprise-grade AI agents with local language support and contextual understanding, accessible via voice and video channels.</li>
<li><strong>Outbound Campaigns: </strong>AI-driven outbound communication to boost customer activation, renewal, and retention.</li>
<li><strong>QA &amp; Analytics: </strong>Real-time monitoring, agent performance scoring, and conversational quality control.</li>
<li><strong>AI Training &amp; E-Learning: </strong>Virtual trainers designed to onboard staff and deliver consistent, on-demand microlearning.</li>
</ul>


Agora Partners With WIZ.AI To Bring Enterprise-Grade AI Agent Solutions To The Market

Biotech

General

GRAL

GRAIL Announces Top-Line Results From Its Galleri PATHFINDER 2 Registrational Study Showing Cancer Detection And A Positive Predictive Value Substantially Higher Than The Previously Published PATHFINDER Study

<p>Empower Semiconductor, the world leader in integrated voltage regulators (IVRs), announced today a collaboration with Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) to develop optimized integrated power solutions for Marvell&#xAE; custom silicon platforms. These advanced solutions are designed to accelerate the transformation of power delivery systems to smaller, faster, integrated power silicon chips tightly coupled with the processor.</p>


MRVL

Empower Semiconductor Collaborates With Marvell Technology To Develop Optimized Integrated Power Solutions For Marvell Custom Silicon Platforms

<p>Analysts' ratings for Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.6, along with a high estimate of $40.00 and a low estimate of $36.00. Observing a 1.08% increase, the current average has risen from the previous average price target of $37.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251676_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Option Care Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Option Care Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Option Care Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Option Care Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OPCH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Option Care Health analyst ratings.</strong></a></p>
<h2>Get to Know Option Care Health Better</h2>
<p>Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.</p>
<h3>Unraveling the Financial Story of Option Care Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Option Care Health's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>16.31%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Option Care Health's net margin is impressive, surpassing industry averages. With a net margin of <strong>3.51%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.39%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Option Care Health's ROA excels beyond industry benchmarks, reaching <strong>1.39%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Option Care Health's debt-to-equity ratio surpasses industry norms, standing at <strong>0.91</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OPCH

Forecasting The Future: 5 Analyst Projections For Option Care Health

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.8, a high estimate of $23.00, and a low estimate of $18.00. No alteration is observed as the current average remains at the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251665_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Plains GP Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Spiro Dounis</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Plains GP Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Plains GP Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Plains GP Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Plains GP Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PAGP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Plains GP Holdings analyst ratings.</strong></a></p>
<h2>About Plains GP Holdings</h2>
<p>Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.</p>
<h3>Plains GP Holdings's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Plains GP Holdings's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>0.13%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Plains GP Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>0.7%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Plains GP Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>6.21%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.3%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Plains GP Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>6.62</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PAGP

Forecasting The Future: 5 Analyst Projections For Plains GP Holdings

<p><i>Leading U.S. companies Apple, Ford, Medtronic, NVIDIA and SpaceX strengthen partnerships with TI to unleash the next era of American innovation</i></p>
<p><strong>NEWS HIGHLIGHTS:</strong></p>
<ul>
<li>More than $60 billion investment includes seven U.S. semiconductor fabs across three manufacturing mega-sites in Texas and Utah supporting more than 60,000 new U.S. jobs</li>
<li>Largest investment in foundational semiconductor manufacturing in U.S. history, building on TI's almost-100-year legacy</li>
<li>TI's largest&nbsp;mega-site in Sherman, Texas includes investment of up to $40 billion dollars for four fabs: SM1 and SM2 – already underway – and two additional fabs, SM3 and SM4</li>
<li>Leverages TI's strengths as a global technology and manufacturing leader to advance critical innovations from vehicles to smartphones to data centers</li>
</ul>
<p>DALLAS, June 18, 2025 /PRNewswire/ --&nbsp;Texas Instruments (TI) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) today announced its plans to invest more than $60 billion across seven U.S. semiconductor fabs, making this the largest investment in foundational semiconductor manufacturing in U.S. history. Working with the Trump administration and building on the company's nearly 100-year legacy, TI is expanding its U.S. manufacturing capacity to supply the growing need for semiconductors that will advance critical innovations from vehicles to smartphones to data centers. Combined, TI's new manufacturing mega-sites in Texas and Utah will support more than 60,000 U.S. jobs.</p>


Texas Instruments Plans To Invest More Than $60B Across Seven U.S. Semiconductor Fabs

<p>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Adaptive Biotechnologies, revealing an average target of $11.2, a high estimate of $15.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 28.0% from the previous average price target of $8.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251656_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Adaptive Biotechnologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adaptive Biotechnologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Adaptive Biotechnologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Adaptive Biotechnologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Adaptive Biotechnologies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ADPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Adaptive Biotechnologies analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Adaptive Biotechnologies</h2>
<p>Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).</p>
<h3>Adaptive Biotechnologies's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Adaptive Biotechnologies showcased positive performance, achieving a revenue growth rate of <strong>25.24%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Adaptive Biotechnologies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-56.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Adaptive Biotechnologies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-15.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-5.68%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Adaptive Biotechnologies's debt-to-equity ratio is below the industry average at <strong>0.46</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ADPT

Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts

<p>4 analysts have expressed a variety of opinions on EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.62, a high estimate of $4.50, and a low estimate of $2.00. A decline of 19.38% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251645_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of EON Resources by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.50</td>
<td>$4.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to EON Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of EON Resources compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for EON Resources's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of EON Resources's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EONR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on EON Resources analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into EON Resources's Background</h2>
<p>EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.</p>
<h3>EON Resources's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> EON Resources's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately <strong>-11.94%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> EON Resources's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-37.69%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> EON Resources's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-24.33%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> EON Resources's ROA excels beyond industry benchmarks, reaching <strong>-1.7%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>3.75</strong>, EON Resources faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EONR

4 Analysts Have This To Say About EON Resources

<p>Goldman Sachs  analyst Suhasini Varanasi   initiates coverage on Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Buy rating and announces Price Target of $280.</p>


FERG

Goldman Sachs Initiates Coverage On Ferguson Enterprises with Buy Rating, Announces Price Target of $280

<p>8 analysts have expressed a variety of opinions on Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $425.0, a high estimate of $510.00, and a low estimate of $380.00. This current average has increased by 6.58% from the previous average price target of $398.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251636_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Charter Communications by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$425.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$510.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$445.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$395.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$400.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$430.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$415.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$380.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Charter Communications. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Charter Communications compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Charter Communications's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Charter Communications's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CHTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Charter Communications analyst ratings.</strong></a></p>
<h2>About Charter Communications</h2>
<p>Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 57 million US homes and businesses, around 35% of the country. Across this footprint, Charter serves 28 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest US cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.</p>
<h3>Charter Communications: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Charter Communications's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>0.41%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Charter Communications's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>8.86%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Charter Communications's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>7.65%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Charter Communications's ROA excels beyond industry benchmarks, reaching <strong>0.81%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>5.88</strong>, Charter Communications faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CHTR

Assessing Charter Communications: Insights From 8 Financial Analysts

<p><strong>Deckers Outdoor's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) short percent of float has fallen 7.01% since its last report. The company recently reported that it has <strong>7.45 million shares sold short</strong>, which is 8.36% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.24 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Deckers Outdoor Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251630_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Deckers Outdoor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Deckers Outdoor's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Deckers Outdoor's peer group average for short interest as a percentage of float is 9.30%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

DECK

Looking Into Deckers Outdoor's Recent Short Interest

<p>Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $30.5, a high estimate of $34.00, and a low estimate of $27.00. Marking an increase of 7.58%, the current average surpasses the previous average price target of $28.35. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251629_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive AT&amp;T is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Simon Flannery</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Choe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$29.50</td>
<td>$29.00</td>
</tr>
<tr>
<td>Vijay Jayant</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$29.00</td>
<td>$28.50</td>
</tr>
<tr>
<td>Timothy Horan</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to AT&amp;T. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AT&amp;T compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of AT&amp;T's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AT&amp;T's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/T/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on AT&amp;T analyst ratings.</strong></a></p>
<h2>Discovering AT&amp;T: A Closer Look</h2>
<p>The wireless business contributes nearly 70% of AT&amp;T's revenue. The firm is the third-largest US wireless carrier, connecting 73 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 15% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential fixed-line services, about 11% of revenue, primarily consist of broadband internet access, serving 14 million customers. AT&amp;T also has a sizable presence in Mexico, with 24 million customers, but this business only accounts for 3% of revenue. The firm has agreed to sell its 70% equity stake in satellite television provider DirecTV to its partner, private equity firm TPG.</p>
<h3>AT&amp;T: Delving into Financials</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> AT&amp;T displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>1.99%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> AT&amp;T's net margin is impressive, surpassing industry averages. With a net margin of <strong>14.35%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> AT&amp;T's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.22%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> AT&amp;T's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.11%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> AT&amp;T's debt-to-equity ratio surpasses industry norms, standing at <strong>1.38</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: AT&T In The Eyes Of 13 Experts

<p><strong>Ball's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) short percent of float has risen 68.1% since its last report. The company recently reported that it has <strong>8.49 million shares sold short</strong>, which is 3.53% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.59 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Ball Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750251625_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Ball has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Ball's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ball's peer group average for short interest as a percentage of float is 4.10%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Comments

Baosheng Media Gr

Baosheng Media Gr (BAOS) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL